Dyadic International (DYAI) Provides Alternative Proteins Business Update

Dyadic International, Inc. (NASDAQ: DYAI) today provided an update on business progress and announced its attendance at the Bioprocess International Conference in Boston, September 23-26, 2024.

At the conference, Dyadic will highlight its C1 and Dapibus™ microbial platforms, which are designed to improve the efficiency and lower the cost of manufacturing recombinant proteins such as:

• Recombinant human albumin: for use in cell culture media, diagnostics, and as a stabilizing agent for vaccine production.
• Bovine transferrin: for use in cell culture media and delivery of cancer therapeutics, among other uses.
• Human lactoferrin: for use in research and pharmaceutical applications as potential antimicrobial, anti-inflammatory, and immune-supportive products.
• Bovine alpha-lactalbumin: for use in products including infant formula, dietary supplements, and functional foods.

As the Company enters the fourth quarter, Dyadic continues to advance partnerships supported by the Dapibus™ platform targeted at the alternative protein market, seeking near-term recurring revenue growth while continuing to advance the C1 platform in the animal and human health markets.

Recent Developments in Alternative Proteins and Life Sciences:

• Proliant Health and Biologicals (“PHB”), a leading manufacturer of proteins serving companies in microbiological, life sciences, biopharmaceutical, and veterinary sciences through its partnership with Dyadic, is expected to launch animal-free recombinant albumin in the first half of 2025 into the approximately $5B serum albumin market. Dyadic received $1 million in payments from PHB in Q3 and expects to receive additional payments after meeting certain productivity goals, and a share of profits from the sales of recombinant albumin products.
• The development of Dyadic’s DNase-I (deoxyribonuclease I) protein has been completed, and product sampling is ongoing. DNase-I is an enzyme that has several key potential applications across different industries, including pharmaceuticals, research, diagnostics, and therapeutic treatments.
• Dyadic’s project to produce recombinant bovine transferrin, used in cell culture media for the alternative protein market, has achieved high productivity, with further optimizations ongoing and application testing in cell culture media expected later this year.
• The development of recombinant human lactoferrin is ongoing, which has potential applications in multiple pharmaceutical and non-pharmaceutical markets.
• A project to produce recombinant bovine growth factor (FGF) is ongoing, with potential applications in cell culture, tissue engineering, stem cell research, and oncology. Initial results are expected in the fourth quarter.

Upcoming Conference:
Bioprocess International 2024
Hynes Convention Center, Boston, USA
September 23-26, 2024

If you would like to schedule a meeting with one of our management members at BPI, please contact Sam Closa at a[email protected].

You May Also Be Interested In

• ExxonMobil outlines key factors for Q2 2026 earnings outlook
• Freedom Broker Starts Holley (HLLY) at Buy
• Exascale Labs and BCAR set shareholder vote for July 29 merger